Markets:

Overview

News

Currencies

International

Treasuries

PTC Therapeutics, Inc. - Common Stock (NQ:PTCT)

77.07 +0.37 (+0.48%)

Streaming Delayed Price Updated: 1:46 PM EST, Jan 7, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about PTC Therapeutics, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9 Next >

PTC Therapeutics Inc (NASDAQ:PTCT): A Prime Candidate for Affordable Growth Investing ↗

January 01, 2026

Via Chartmill

PTC THERAPEUTICS INC (NASDAQ:PTCT) Shows High-Growth Momentum and Bullish Technical Setup ↗

December 15, 2025

PTC Therapeutics stock shows strong earnings momentum and a top-rated technical setup, offering a potential breakout opportunity for growth investors.

Via Chartmill

PTC Therapeutics Inc (NASDAQ:PTCT) Presents a Compelling Growth and Technical Setup ↗

December 13, 2025

PTC Therapeutics (PTCT) exemplifies a strong growth stock with a bullish technical setup, combining high sales growth, robust margins, and a potential chart breakout.

Via Chartmill

PTC Therapeutics Inc (NASDAQ:PTCT): A GARP Stock with Strong Growth and Reasonable Valuation ↗

December 10, 2025

PTC Therapeutics offers high growth at a fair price, with strong earnings and revenue increases, trading below industry valuations.

Via Chartmill

Healthcare Investor Exits $13 Million Stake STAAR Surgical Stake as Alcon Deal Drama Looms ↗

December 03, 2025

One specialist investor just walked away from STAAR Surgical entirely—right as uncertainty over a delayed Alcon deal looms.

Via The Motley Fool

Topics Regulatory Compliance

Rare-Disease Biotech PTC Is Surging — And One Fund Just Raised Its Bet. Should You? ↗

December 02, 2025

Via The Motley Fool

Earnings Scheduled For November 4, 2025 ↗

November 04, 2025

Via Benzinga

PTC Therapeutics Swings to a Profit on $211 Million in Revenue — Is This Why a Major Fund Just Invested $32 Million? ↗

December 03, 2025

PTC’s turnaround quarter is raising eyebrows—here’s why one major investor just doubled down.

Via The Motley Fool

Topics Regulatory Compliance

Dyne Therapeutics Stock Down 30% in a Year — So Why Did One Investor Add Nearly 1 Million Shares? ↗

December 03, 2025

Dyne Therapeutics Stock Down 30% in a Year — So Why Did One Investor Add Nearly 1 Million Shares?

Via The Motley Fool

Topics Regulatory Compliance

Capricor Therapeutics (NASDAQ: CAPR) Soars 535% to Eight-Year High on Landmark Duchenne Muscular Dystrophy Treatment Results

December 03, 2025

December 3, 2025 – Capricor Therapeutics (NASDAQ: CAPR) has sent shockwaves through the biotech sector today, witnessing an astonishing 535% surge in its stock price, propelling the company to an...

Via MarketMinute

Aurinia Raises Guidance and Shares Are Surging— Is This Why a Major Investor Just Boosted Its Stake? ↗

December 02, 2025

A top life sciences investor is doubling down as Aurinia’s flagship therapy gains momentum—here’s what long-term shareholders should watch next.

Via The Motley Fool

A PTC Therapeutics (PTCT) Insider Sold 10,000 Shares for $795,000 ↗

November 29, 2025

Focused on rare disease therapies, this biotech company reported a significant insider sale amid strong recent share price gains.

Via The Motley Fool

Topics Regulatory Compliance

PTC THERAPEUTICS INC (NASDAQ:PTCT) Presents an Affordable Growth Opportunity ↗

November 19, 2025

PTC Therapeutics offers strong growth and solid financials at a fair price, making it an attractive stock for investors seeking affordable expansion opportunities.

Via Chartmill

This Fund Sold $30 Million in PTC Therapeutics Shares Amid a 93% Rally: Here’s Why ↗

November 18, 2025

A healthcare hedge fund just trimmed its biggest holding—right as the company posts a clinical and financial breakout year.

Via The Motley Fool

Topics Regulatory Compliance

Why This Fund Trimmed a $161 Million Travere Position After a 100% Rally ↗

November 18, 2025

A healthcare hedge fund just locked in gains on one of its biggest winners—here’s what that move really signals.

Via The Motley Fool

PTC THERAPEUTICS INC (NASDAQ:PTCT) Shows Strong Growth Momentum and Technical Health ↗

November 13, 2025

PTC Therapeutics (PTCT) shows explosive earnings growth of 277% and strong technicals, presenting a high-momentum investment opportunity.

Via Chartmill

Sarepta Therapeutics Shares Plummet as Key DMD Treatments Miss Primary Endpoint in Late-Stage Trial

November 04, 2025

Sarepta Therapeutics Inc. (NASDAQ: SRPT) experienced a dramatic downturn in its stock valuation today, November 4, 2025, following the announcement of disappointing results from a pivotal late-stage...

Via MarketMinute

Topics Death

PTC THERAPEUTICS INC (NASDAQ:PTCT) Presents a Compelling Mix of Strong Growth and Bullish Technical Setup ↗

October 30, 2025

PTC Therapeutics (PTCT) shows strong growth with 96% revenue surge and a bullish technical breakout pattern, making it a compelling biotech stock.

Via Chartmill

PTC THERAPEUTICS INC (NASDAQ:PTCT) Presents an Affordable Growth Opportunity ↗

October 25, 2025

PTC Therapeutics offers strong growth and attractive valuation metrics, making it a compelling affordable growth stock for investors seeking biotech opportunities.

Via Chartmill

PTC THERAPEUTICS INC (NASDAQ:PTCT) Presents a Compelling Case for Affordable Growth Investing ↗

October 02, 2025

PTC Therapeutics (PTCT) offers strong growth with a 96% revenue surge, yet trades at a reasonable P/E of 10.94, making it a compelling GARP investment.

Via Chartmill

PTC THERAPEUTICS INC (NASDAQ:PTCT) Combines Strong Growth with Bullish Technical Setup ↗

September 30, 2025

PTC Therapeutics (PTCT) combines explosive sales growth and strong earnings with an attractive valuation and bullish technical setup for a compelling investment profile.

Via Chartmill

PTC THERAPEUTICS INC (NASDAQ:PTCT): An Affordable Growth Candidate in Biotech ↗

September 11, 2025

PTC Therapeutics (PTCT) offers strong growth & attractive valuation. With revenue up 96% and a low P/E of 10.29, it's a top affordable growth stock pick in biotech.

Via Chartmill

PTC Therapeutics Could Challenge BioMarin For Metabolic Disorder Treatment ↗

September 08, 2025

BioMarin's Palynziq significantly lowered blood phenylalanine in teens with PKU, with nearly half reaching target levels in the Phase 3 study.

Via Benzinga

Here's Why Shares in PTC Therapeutics Soared This Week ↗

September 05, 2025

An upbeat presentation helped highlight the potential for the company's leading drug to be commercially successful.

Via The Motley Fool

PTC Therapeutics Stock Is Stuck In A Multi-Year Slump ↗

August 21, 2025

PTC Therapeutics is stuck with uncertainty stretching through 2030. Here's why the stock remains a long-term avoid.

Via Benzinga

PTC THERAPEUTICS INC (NASDAQ:PTCT) Emerges as a Top Affordable Growth Stock ↗

August 21, 2025

Discover PTC Therapeutics (PTCT), an affordable growth stock with strong revenue & EPS growth, low P/E ratio, and solid profit margins in the biotech sector.

Via Chartmill

PTC Therapeutics Stock In The Spotlight After FDA Refuses Approval For Drug To Treat Neurodegenerative Disease, Analysts Are Divided ↗

August 19, 2025

Via Stocktwits

PTC Therapeutics Faces FDA Rejection On Rare Disease Treatment Over Efficacy Concerns ↗

August 19, 2025

FDA rejected PTC Therapeutics' vatiquinone for Friedreich's ataxia, citing insufficient efficacy data and requiring another controlled trial.

Via Benzinga

PTCT Earnings Beat but Sales Drop 4% ↗

August 07, 2025

Via The Motley Fool

Topics Earnings

PTC THERAPEUTICS INC (NASDAQ:PTCT) Reports Q2 2025 Earnings Beat with Narrowed Loss and Strong Sephience™ Launch ↗

August 07, 2025

PTC Therapeutics (PTCT) reported strong Q2 2025 earnings, beating revenue estimates at $179M and narrowing EPS loss. Growth driven by Sephience™ launch for PKU in U.S. & Europe. Stock up 5.4% in a...

Via Chartmill

Topics Earnings

< Previous 1 2 3 4 5 6 7 8 9 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.